Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Rule, S.
725  Ergebnisse:
Personensuche X
?
1

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology.  41 (2023)  S2 - p. 249-250 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Long term follow‐up of untreated/relapsing MCL patients wit..:

Le Gouill, S. ; Morschhauser, F. ; Chiron, D....
Hematological Oncology.  41 (2023)  S2 - p. 478-479 , 2023
Link: https://doi.org/10.1002/..
 
?
3

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERAT..:

Le Gouill, S. ; Długosz-Danecka, M. ; Rule, S....
HemaSphere.  6 (2022)  - p. 1021-1022 , 2022
Link: https://doi.org/10.1097/..
 
?
4

P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACT..:

Owen, R. ; McCarthy, H. ; Rule, S....
HemaSphere.  6 (2022)  - p. 1020-1021 , 2022
Link: https://doi.org/10.1097/..
 
?
5

TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE ..:

Villa, D. ; Jiang, A. ; Crosbie, N....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACT..:

Wang, M. ; Rule, S. ; Zinzani, P. L....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

Favourable outcomes for high-risk diffuse large B-cell lymp..:

McMillan, A.K. ; Phillips, E.H. ; Kirkwood, A.A....
Annals of Oncology.  31 (2020)  9 - p. 1251-1259 , 2020
Link: https://doi.org/10.1016/..
 
?
8

Rainforest, woodland or swampland? Integrating time, space ..:

Lynch, A. J. J. ; Ferrier, Å. ; Ford, A. J....
Landscape Ecology.  35 (2019)  1 - p. 83-99 , 2019
Link: https://doi.org/10.1007/..
 
?
9

LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIF..:

Korfi, K. ; Araf, S. ; Bewicke‐Copley, F....
Hematological Oncology.  37 (2019)  S2 - p. 142-143 , 2019
Link: https://doi.org/10.1002/..
 
?
10

EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANE..:

Rule, S. ; Barreto, W.G. ; Briones, J....
Hematological Oncology.  37 (2019)  S2 - p. 229-231 , 2019
Link: https://doi.org/10.1002/..
 
?
11

NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESP..:

Pettitt, A.R. ; Barrington, S. ; Kalakonda, N....
Hematological Oncology.  37 (2019)  S2 - p. 67-68 , 2019
Link: https://doi.org/10.1002/..
 
?
12

OUTCOMES IN FIRST RELAPSED‐REFRACTORY YOUNGER PATIENTS WITH..:

Visco, C. ; Di Rocco, A. ; Tisi, M.C....
Hematological Oncology.  37 (2019)  S2 - p. 46-47 , 2019
Link: https://doi.org/10.1002/..
 
?
13

IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NER..:

Rusconi, C. ; Tucker, D. ; Bernard, S....
Hematological Oncology.  37 (2019)  S2 - p. 244-245 , 2019
Link: https://doi.org/10.1002/..
 
?
14

Updated results from the phase 3 HELIOS study of ibrutinib,..:

Fraser, G. ; Cramer, P. ; Demirkan, F....
Leukemia.  33 (2018)  4 - p. 969-980 , 2018
Link: https://doi.org/10.1038/..
 
?
15

Ibrutinib versus temsirolimus: 3-year follow-up of patients..:

Rule, S ; Jurczak, W ; Jerkeman, M...
Leukemia.  32 (2018)  8 - p. 1799-1803 , 2018
Link: https://doi.org/10.1038/..
 
1-15